News Medical

Molnupiravir reduces long-term COVID-19 symptoms but shows limited impact on hospitalizations

Molnupiravir speeds up recovery and eases long-term symptoms, but its minimal effect on hospitalizations raises questions about its broader impact on COVID-19 care. Study: Health outcomes 3 months and ...

Where is flu, COVID surging? Here’s where people are filling prescriptions for Tamiflu, Paxlovid, and more

GoodRx reports on tracking prescription fills for flu and COVID-19 treatments, revealing seasonal trends and insurance ...
Healio

Molnupiravir cuts risk for severe COVID-19 symptoms — and possibly long COVID

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The antiviral reduced the risk for severe symptoms of ...
McKnight's Long-Term Care News

COVID-19 drug molnupiravir linked to lower death risk in older adults, study finds

The antiviral drug molnupiravir (Lagevrio) slashed the risk of death from COVID-19 in half when given early to older adults. It also lowered all-cause deaths among older adults in the Czech Republic ...
Medscape

Molnupiravir and Nirmatrelvir-Ritonavir Provide No Benefit in Hospitalized COVID-19 Patients

In patients hospitalized with COVID-19, adding molnupiravir or nirmatrelvir-ritonavir to usual care was not associated with improved clinical outcomes, including 28-day mortality duration of hospital ...
Medscape

Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.

Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H Broad-spectrum antiviral agents targeting viral RNA-dependent RNA polymerase (RdRp) are expected to ...